Quarterly ResultAug 5, 2026, 08:08 AM
ImageneBio Q2 Net Loss $10.2M; Cash $136.2M
AI Summary
ImageneBio, Inc. reported a net loss of $10.2 million, or $0.63 per share, for the second quarter ended June 30, 2026, an improvement from a net loss of $10.7 million in the same period last year. The company ended the quarter with $136.2 million in cash, cash equivalents, and marketable securities, providing funding into the first quarter of 2028. ImageneBio also provided updates on its clinical programs, including the ongoing Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis and plans to initiate a Phase 2 trial for alopecia areata in 2026. Additionally, the company strengthened its leadership team with new appointments for Chief Financial Officer and General Counsel.
Key Highlights
- Net loss for Q2 2026 was $10.2 million, compared to $10.7 million in Q2 2025.
- Net loss per common share was $0.63 for Q2 2026, down from $4.46 in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $136.2 million as of June 30, 2026.
- Funding is anticipated to be sufficient for planned operations into Q1 2028.
- R&D expenses increased to $6.7 million in Q2 2026 from $5.7 million in Q2 2025.
- G&A expenses rose to $5.1 million in Q2 2026 from $1.7 million in Q2 2025.
- Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis continues, with topline data expected in Q4 2027.
- Initiation of a Phase 2 clinical trial for olevaprubart in alopecia areata is planned for 2026.
- Yanina Grant-Huerta appointed as Chief Financial Officer and Matt Robbins as General Counsel.
Price Impact
More from IMA